期刊文献+

天然产物抗乳腺肿瘤纳米给药系统研究进展 被引量:3

Advances in the Research of Natural Products Anti-Breast Tumor Nanometer Drug Delivery System
原文传递
导出
摘要 乳腺肿瘤常发于女性且死亡率高。天然产物在乳腺肿瘤治疗上有独特的优势,但水溶性差、生物利用度低、选择性差、易发生不良反应等缺点限制了其在临床上的发展应用。纳米技术的迅猛发展使其成为药物递送的理想载体,其可克服天然产物的原生缺陷,为更多天然产物发展为良好的抗乳腺肿瘤备选药物提供了可能。大量研究表明,纳米给药系统在天然产物抗乳腺肿瘤临床应用中具有广阔前景。笔者就天然产物抗乳腺肿瘤纳米给药系统研究进展展开综述。 Breast tumors often occur in women and have a high mortality rate.Natural products have unique advantages in the treatment of breast tumors,but the disadvantages such as poor water solubility,low bioavailability,poor selectivity and easy to produce adverse reactions limit their clinical application.The rapid development of nanotechnology makes it an ideal vehicle for drug delivery,which can overcome the original defects of natural products and provide the possibility for the development of more natural products as good anti-breast tumor drug candidates.A large number of studies have shown that nano drug delivery system has a broad prospect in the clinical application of natural products against breast tumors.In this paper,the research progress of nano drug delivery system of natural products against breast tumor is reviewed.
作者 张攀 汪子翔 张宜凡 陈群力 姚虹 杜望春 赵梅 ZHANG Pan;WANG Zi-xiang;ZHANG Yi-fan;CHEN Qun-li;YAO Hong;DU Wang-chun;ZHAO Mei(Graduate school,Shanghai University of Chinese Medicine,Shanghai 201203,China;Department of Pharmacy,Shanghai University of Medicine&Health Sciences,Shanghai 201318,China;Shanghai University of Chinese Medicine,Shanghai 201203,China)
出处 《中国药学杂志》 CAS CSCD 北大核心 2021年第6期429-435,共7页 Chinese Pharmaceutical Journal
基金 国家自然科学基金青年项目资助(81602729)。
关键词 天然产物 纳米给药系统 乳腺肿瘤 natural product nanoparticulate delivery system breast cancer
  • 相关文献

参考文献4

二级参考文献52

  • 1杨翠红,张玉民,刘金剑,刘鉴峰,吴红英,褚丽萍.RGD功能化多肽纳米纤维的制备及其体内肿瘤靶向性研究[J].中国生化药物杂志,2014,34(5):5-8. 被引量:3
  • 2杨婉华,汪蕊,陈睿,马湘一,王世宣,卢运萍,马丁.αv整联蛋白拮抗剂RGD肽对乳腺癌细胞增殖侵袭能力影响的研究[J].肿瘤,2006,26(8):728-731. 被引量:3
  • 3Ikemoto S, Sugimura K, Kuratukuri K, et al. Antitumor effects of lipoxygenase inhibitors on murine bladder cancer cell line (MBT-2) [J]. Anticancer Res, 2004, 24(2B): 733-738.
  • 4Wang N, Tang L J, Zhu G Q. Apoptosis induced by baicalin involving up-regulation of P53 and bax in MCF-7 cells [J]. JAsian Prod Res, 2008, 10(11/12): 1129-1235.
  • 5Chen J, Li Z, Chen A Y. Inhibitory effect of baicalin and baicalein on ovarian cancer cells [J]. Int JMol Sci, 2013, 14(3): 6012-6025.
  • 6Wang X F, Zhou Q M, Du J. Baicalin suppresses migration, invasion and metastasis of breast cancer via p38MAPK signaling pathway [J]. Anticancer Agents Med Chem, 2013, 13(6): 923-931.
  • 7Liu Z D, Zhang X H, Wu H Y, et al. Preparation and evaluation of solid lipid nanoparticles of BCN for ocular drug delivery system in vitro and in vivo [J]. Drug Dev IndPharm, 2011, 37(4): 475-481.
  • 8Chen Y J, Jia Y, Jin R X, et al. Preparation of BCN flexible nano-liposomes [J]. Chin J Exp Tradit Med Formula, 2011, 17(5): 1-4.
  • 9Wang C, Zhao X M, Hao J F, et al. The process on new technology and novel dosage form to improve the bioavailability of BCN [J]. Chin Tradit Pat Med, 2012, 34(3): 545-549.
  • 10Mikhail A S, Allen C. Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels [J]. J Controlled Release, 2009, 138(3): 214-223.

共引文献37

同被引文献40

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部